3Q EARNINGS: Will Actavis, CEO Saunders continue deal streak?
This article was originally published in Scrip
Actavis won't let its massive debt position – $15.1bn as of the third quarter of 2014 – get in the way of its dealmaking track record, including large transactions, which may or may not include the specialty biopharmaceutical company Allergan.
You may also be interested in...
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.